CD8+ T cells complement antibodies in protecting against yellow fever virus

Journal of Immunology

Volumn 194, Issue 3, 2015, Pages 1141-1153

  Bassi, Maria R ^a   Kongsgaard, Michael ^a   Steffensen, Maria A ^a   Fenger, Christina ^b   Rasmussen, Michael ^a   Skjødt, Karsten ^b   Finsen, Bente ^b   Stryhn, Anette ^a   Buus, Søren ^a   Christensen, Jan P ^a   Thomsen, Allan R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; YELLOW FEVER VACCINE; CD40 LIGAND; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMORAL IMMUNITY; IN VIVO STUDY; INFECTION CONTROL; INFECTION PREVENTION; LONG TERM SURVIVAL; LYMPHOCYTE FUNCTION; MOUSE; MOUSE STRAIN; NONHUMAN; SPLEEN CELL; T CELL DEPLETION; VIRAL CLEARANCE; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ADAPTIVE IMMUNITY; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE DEPLETION; METABOLISM; MORTALITY; NEUTROPHIL CHEMOTAXIS; PASSIVE IMMUNIZATION; VACCINATION; VIROLOGY; YELLOW FEVER VIRUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTAXIS, LEUKOCYTE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; VACCINATION; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84921507552     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402605     Document Type: Article

References (58)

1. Monath, T. P. 2005. Yellow fever vaccine. Expert Rev. Vaccines 4: 553-574.
2. Theiler, M., and H. H. Smith. 1937. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65: 787-800.
3. Theiler, M., and H. H. Smith. 1937. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J. Exp. Med. 65: 767-786.
4. Reinhardt, B., R. Jaspert, M. Niedrig, C. Kostner, and J. L'age-Stehr. 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 56: 159-167.
5. Miller, J. D., R. G. van der Most, R. S. Akondy, J. T. Glidewell, S. Albott, D. Masopust, K. Murali-Krishna, P. L. Mahar, S. Edupuganti, S. Lalor, et al. 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
6. Co, M. D., M. Terajima, J. Cruz, F. A. Ennis, and A. L. Rothman. 2002. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293: 151-163.
7. Bonaldo, M. C., M. A. Martins, R. Rudersdorf, P. A. Mudd, J. B. Sacha, S. M. Piaskowski, P. C. Costa Neves, M. G. Veloso de Santana, L. Vojnov, S. Capuano, III, et al. 2010. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J. Virol. 84: 3699-3706.
8. Guirakhoo, F., R. Weltzin, T. J. Chambers, Z. X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath. 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74: 5477-5485.
9. McAllister, A., A. E. Arbetman, S. Mandl, C. Peña-Rossi, and R. Andino. 2000. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J. Virol. 74: 9197-9205.
10. Nogueira, R. T., A. R. Nogueira, M. C. Pereira, M. M. Rodrigues, P. C. Neves, R. Galler, and M. C. Bonaldo. 2013. Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS ONE 8: e59347.
11. Querec, T., S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, and B. Pulendran. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203: 413-424.
12. Barba-Spaeth, G., R. S. Longman, M. L. Albert, and C. M. Rice. 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 202: 1179-1184.
13. Akondy, R. S., N. D. Monson, J. D. Miller, S. Edupuganti, D. Teuwen, H. Wu, F. Quyyumi, S. Garg, J. D. Altman, C. Del Rio, et al. 2009. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 183: 7919-7930.
14. Blom, K., M. Braun, M. A. Ivarsson, V. D. Gonzalez, K. Falconer, M. Moll, H. G. Ljunggren, J. Michaëlsson, and J. K. Sandberg. 2013. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector-to a memory-type response. J. Immunol. 190: 2150-2158.
15. Nansen, A., T. Jensen, J. P. Christensen, S. O. Andreasen, C. Röpke, O. Marker, and A. R. Thomsen. 1999. Compromised virus control and augmented perforinmediated immunopathology in IFN-gamma-deficient mice infected with lymphocytic choriomeningitis virus. J. Immunol. 163: 6114-6122.
16. van der Most, R. G., L. E. Harrington, V. Giuggio, P. L. Mahar, and R. Ahmed. 2002. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296: 117-124.
17. Toft-Hansen, H., R. K. Nuttall, D. R. Edwards, and T. Owens. 2004. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J. Immunol. 173: 5209-5218.
18. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 29: e45.
19. Cobbold, S., G. Martin, and H. Waldmann. 1986. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation 42: 239-247.
20. Brandriss, M. W., J. J. Schlesinger, E. E. Walsh, and M. Briselli. 1986. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 67: 229-234.
21. Schlesinger, J. J., M. W. Brandriss, and E. E. Walsh. 1985. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J. Immunol. 135: 2805-2809.
22. Putnak, J. R., and J. J. Schlesinger. 1990. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J. Gen. Virol. 71: 1697-1702.
23. Meier, K. C., C. L. Gardner, M. V. Khoretonenko, W. B. Klimstra, and K. D. Ryman. 2009. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 5: e1000614.
24. Thibodeaux, B. A., N. C. Garbino, N. M. Liss, J. Piper, C. D. Blair, and J. T. Roehrig. 2012. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 30: 3180-3187.
25. Christensen, J. P., S. O. Kauffmann, and A. R. Thomsen. 2003. Deficient CD4+ T cell priming and regression of CD8+ T cell functionality in virus-infected mice lacking a normal B cell compartment. J. Immunol. 171: 4733-4741.
26. Thomsen, A. R., J. Johansen, O. Marker, and J. P. Christensen. 1996. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. J. Immunol. 157: 3074-3080.
27. Vinuesa, C. G., S. G. Tangye, B. Moser, and C. R. Mackay. 2005. Follicular B helper T cells in antibody responses and autoimmunity. Nat. Rev. Immunol. 5: 853-865.
28. Schaerli, P., K. Willimann, A. B. Lang, M. Lipp, P. Loetscher, and B. Moser. 2000. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192: 1553-1562.
29. Voigt, I., S. A. Camacho, B. A. de Boer, M. Lipp, R. Förster, and C. Berek. 2000. CXCR5-deficient mice develop functional germinal centers in the splenic T cell zone. Eur. J. Immunol. 30: 560-567.
30. Andreasen, S. O., J. E. Christensen, O. Marker, and A. R. Thomsen. 2000. Role of CD40 ligand and CD28 in induction and maintenance of antiviral CD8+ effector T cell responses. J. Immunol. 164: 3689-3697.
31. Wiesel, M., N. Joller, A. K. Ehlert, J. Crouse, R. Spörri, M. F. Bachmann, and A. Oxenius. 2010. Th cells act via two synergistic pathways to promote antiviral CD8+ T cell responses. J. Immunol. 185: 5188-5197.
32. Clarke, S. R. 2000. The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J. Leukoc. Biol. 67: 607-614.
33. Bevan, M. J. 2004. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4: 595-602.
34. Hsieh, M. F., S. L. Lai, J. P. Chen, J. M. Sung, Y. L. Lin, B. A. Wu-Hsieh, C. Gerard, A. Luster, and F. Liao. 2006. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J. Immunol. 177: 1855-1863.
35. Klein, R. S., E. Lin, B. Zhang, A. D. Luster, J. Tollett, M. A. Samuel, M. Engle, and M. S. Diamond. 2005. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79: 11457-11466.
36. Larena, M., M. Regner, E. Lee, and M. Lobigs. 2011. Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis. J. Virol. 85: 5446-5455.
37. Metcalf, T. U., and D. E. Griffin. 2011. Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system. J. Virol. 85: 11490-11501.
38. Tschen, S. I., S. A. Stohlman, C. Ramakrishna, D. R. Hinton, R. D. Atkinson, and C. C. Bergmann. 2006. CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS. Eur. J. Immunol. 36: 603-612.
39. Galler, R., K. V. Pugachev, C. L. Santos, S. W. Ocran, A. V. Jabor, S. G. Rodrigues, R. S. Marchevsky, M. S. Freire, L. F. Almeida, A. C. Cruz, et al. 2001. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290: 309-319.
40. Pulendran, B. 2009. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9: 741-747.
41. Schlesinger, J. J., M. Foltzer, and S. Chapman. 1993. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192: 132-141.
42. Gould, E. A., A. Buckley, A. D. Barrett, and N. Cammack. 1986. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67: 591-595.
43. Larena, M., N. A. Prow, R. A. Hall, N. Petrovsky, and M. Lobigs. 2013. JEADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody. J. Virol. 87: 4395-4402.
44. Bedenikovic, G., J. Crouse, and A. Oxenius. 2014. T-cell help dependence of memory CD8+ T-cell expansion upon vaccinia virus challenge relies on CD40 signaling. Eur. J. Immunol. 44: 115-126.
45. Sitati, E., E. E. McCandless, R. S. Klein, and M. S. Diamond. 2007. CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J. Virol. 81: 9801-9811.
46. Belz, G. T., D. Wodarz, G. Diaz, M. A. Nowak, and P. C. Doherty. 2002. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J. Virol. 76: 12388-12393.
47. von Herrath, M. G., M. Yokoyama, J. Dockter, M. B. Oldstone, and J. L. Whitton. 1996. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70: 1072-1079.
48. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188: 2199-2204.
49. Christensen, J. P., O. Marker, and A. R. Thomsen. 1994. The role of CD4+ T cells in cell-mediated immunity to LCMV: studies in MHC class I and class II deficient mice. Scand. J. Immunol. 40: 373-382.
50. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
51. Liu, T., and T. J. Chambers. 2001. Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J. Virol. 75: 2107-2118.
52. Yauch, L. E., R. M. Zellweger, M. F. Kotturi, A. Qutubuddin, J. Sidney, B. Peters, T. R. Prestwood, A. Sette, and S. Shresta. 2009. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182: 4865-4873.
53. Shrestha, B., and M. S. Diamond. 2004. Role of CD8+ T cells in control of West Nile virus infection. J. Virol. 78: 8312-8321.
54. Shrestha, B., T. Ng, H. J. Chu, M. Noll, and M. S. Diamond. 2008. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26: 2020-2033.
55. Goncalvez, A. P., C. H. Chien, K. Tubthong, I. Gorshkova, C. Roll, O. Donau, P. Schuck, S. Yoksan, S. D. Wang, R. H. Purcell, and C. J. Lai. 2008. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J. Virol. 82: 7009-7021.
56. Gupta, A. K., V. J. Lad, and A. A. Koshy. 2003. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies. Acta Virol. 47: 141-145.
57. Kimura-Kuroda, J., and K. Yasui. 1988. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141: 3606-3610.
58. Murali-Krishna, K., V. Ravi, and R. Manjunath. 1996. Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. J. Gen. Virol. 77: 705-714.